South Plainfield-based PTC Therapeutics Inc. announced Thursday the pricing of its public offering of 4.49 million shares of common stock at a price of $24.50 per share.
According to the release, J.P. Morgan and Credit Suisse are acting as joint lead book-running managers for the offering. Registration to these securities was declared effective by the Securities and Exchange Commission on Feb. 12.
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy